Treats serious infections caused by susceptible strains of the designated microorganisms…. Sold as Claforan, Claforan In Sodium Chloride 0.9% In Plastic Container, Claforan In Dextrose 5% In Plastic Container, Cefotaxime And Dextrose 2.4% In Plastic Container, Cefotaxime And Dextrose 3.9% In Plastic Container. Every FDA application for this active ingredient: 3 branded and 14 generic.
As of Nov 16, 2026, FDA lists 17 applications for Cefotaxime Sodium (sold as Claforan, Claforan In Sodium Chloride 0.9% In Plastic Container, Claforan In Dextrose 5% In Plastic Container and others), first approved Mar 11, 1981, with 1 new use approved and 0 published complete response letters.
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Cefotaxime Sodium Powder, for Solution | Current | Feb 17, 2015 | Oct 14, 2026 |
| Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant PatientsIncidence of Infectious Diseases · Pomeranian Medical University Szczecin | Not applicable | Recruiting | Dec 29, 2025 |
| PRophylaxis Against Early VENTilator-associated Infections in Acute Brain InjuryAll-cause Mortality, Quality of Life · The George Institute | Phase 3 | Recruiting | Feb 11, 2025 |
| Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL ReconstructionInfection, Bacterial · University of Duhok | Not applicable | Recruiting | Dec 12, 2023 |
| Mar 11, 1981 | ClaforanNDA 50547 · New molecular entity | Sterimax | 53 | Marketed |
| May 20, 1985 | Claforan In Sodium Chloride 0.9% In Plastic Container, Claforan In Dextrose 5% In Plastic ContainerNDA 50596 · New dosage form | Sterimax | 30 | Discontinued |
| Jan 13, 1987 | ClaforanANDA 62659 | Sanofi Aventis US | 29 | Discontinued |
| Mar 24, 2000 | CefotaximeANDA 64200 | Fresenius Kabi USA | 9 | Discontinued |
| Mar 24, 2000 | CefotaximeANDA 64201 | Fresenius Kabi USA | 9 | Discontinued |
| Nov 20, 2002 | CefotaximeANDA 65071 | Hikma | 3 | Discontinued |
| Nov 20, 2002 | CefotaximeANDA 65072 | Hikma | 3 | Discontinued |
| Sep 24, 2003 | Cefotaxime SodiumANDA 65124 | Lupin | 3 | Discontinued |
| Jul 29, 2004 | Cefotaxime And Dextrose 2.4% In Plastic Container, Cefotaxime And Dextrose 3.9% In Plastic ContainerNDA 50792 · New formulation or manufacturer | B Braun | 1 | Discontinued |
| Aug 10, 2006 | Cefotaxime SodiumANDA 65292 | Hospira Inc | 1 | Discontinued |
| Aug 10, 2006 | Cefotaxime SodiumANDA 65293 | Hospira Inc | 1 | Discontinued |
| Aug 11, 2006 | Cefotaxime SodiumANDA 65290 | Hospira Inc | 1 | Discontinued |
| Aug 29, 2006 | Cefotaxime, Cefotaxime SodiumANDA 65197 | Wockhardt | 2 | Discontinued |
| Nov 5, 2009 | Cefotaxime SodiumANDA 65516 | Aurobindo Pharma Ltd | 0 | Discontinued |
| Nov 5, 2009 | Cefotaxime SodiumANDA 65517 | Aurobindo Pharma | 0 | Discontinued |
| Jan 25, 2010 | Cefotaxime SodiumANDA 65348 | Cephazone Pharma | 0 | Discontinued |
| Feb 19, 2016 | Cefotaxime SodiumANDA 203132 | Hospira | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA